// App-Quantinova.ai

1686 : Efficacy and Safety of Concomitant Use of Ravulizumab and IST in Patients with Paroxysmal Nocturnal Hemoglobinuria up to 52 Weeks

Researchers

Presenter

  • Hubert Schrezenmeier

Principal Investigators

  • Jong Wook Lee

  • Anita Hill

  • Vadim V Ptushkin

  • Viviani Pessoa

  • Rosario Notaro

  • Jimmy Wang

  • Masayo Ogawa

  • Shinichiro Okamoto

  • Lily LL Wong

  • Regis Peffault De Latour

  • Austin G Kulasekararaj

Medical Centers

  • Institute of Transfusion Medicine, University of Ulm, and Institute for Clinical Transfusion Medicine and Immunogenetics, German Red Cross Blood Transfusion Service Baden-Württemberg-Hessen and University Hospital Ulm,Ulm,Germany

  • Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea

  • Vertex Pharmaceuticals Inc., Boston, MA

  • Outpatient department for hematology oncology and chemotherapy,S.P.Botkin hospital,Moscow,Russian Federation

  • Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

  • Laboratory of Cancer Genetics and Gene Transfer, Core Research Laboratory - Istituto per lo Studio, la Prevenzione e la Rete Oncologica (ISPRO), Florence, Italy

  • Alexion Pharmaceuticals Inc., Cheshire, CT

  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, Keio University, Tokyo, Japan

  • Hematology Unit, Queen Elizabeth Hospital, Kota Kinabalu,Sabah,Malasia

  • Hematology/Transplantation, Hospital Saint Louis, Paris, France

  • King’s College Hospital NHS Foundation Trust, King’s College, London, UK, and NIHR Wellcome King’s Clinical Research Facility, London, United Kingdom

Locations

  • Germany

  • Republic of South Korea

  • United States

  • Russia

  • United Kingdom

  • Italy

  • Japan

  • Malaysia

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Paroxysmal nocturnal hemoglobinuria

Biomarkers

  • N/A

Drug/Treatment

  • Eculizumab

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Multicenteric

  • Controlled

Phase

  • III

Study Id's

  • NCT02946463

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved